Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcNΔnlpIIHCL
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EcNΔnlpIIHCL (ENHL) is an engineered microbial therapy derived from the probiotic strain *Escherichia coli* Nissle 1917 (EcN). The bacterium is genetically modified with a deletion of the *nlpI* gene to enhance the biogenesis of outer membrane vesicles (OMVs), which serve as delivery vehicles for therapeutic payloads. ENHL features a bifunctional surface display system utilizing Ice Nucleation Protein (INP)-HlpA for tumor-specific targeting and ClyA-EGFP for visualization and tracking. It is further engineered with an arabinose-inducible system to express lactate oxidase (LOx) within the tumor microenvironment (TME). Administered orally, the bacteria selectively colonize tumor tissues where the localized expression of LOx depletes lactate, thereby neutralizing acidic stress, inhibiting aberrant DNA repair, and promoting immune cell infiltration. This metabolic reprogramming strategy is primarily designed to overcome radioresistance in colorectal cancer and enhance the overall efficacy of radiotherapy.
- Other names
- LOx-expressing EcNΔnlpIEngineered Escherichia coli Nissle 1917 delta-nlpI IHCL
02
Targets
L-lactate
Beyond the preview
Go deeper on EcNΔnlpIIHCL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcNΔnlpIIHCL.